Collaborative Clinical Study Aims to Advance Treatment of Kidney and Prostate Cancer with 3D Printing
Patient-specific and highly personalized 3D models being studied for their ability to enable surgeons to more effectively conduct pre-surgical planning and intra-operative collaboration
Stratasys J750 3D Printer empowers researchers to accurately replicate complex organs and pathologies in highly accurate, full-color 3D printed physical models
This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171023006120/en/
The two-year clinical trial is being led by
Under the randomized, controlled study, Wake and her research team are 3D printing kidney and prostate cancer models for a sample of the participating 300 patients – measuring the specific impact each has on pre-surgical planning versus traditional 2D visualization approaches. Subjects are separated into three treatment categories to analyze and compare conventional pre-operative 2D imaging, augmented reality models, and next-generation 3D printed models.
“3D printing holds a lot of potential in assisting with surgical planning, and as surgeons, we are always looking at ways to improve outcomes for our patients,” says study co-author
“Surgeons and hospitals continuously search for ways to improve the quality of patient care while also reining in procedural costs. In case studies and small trials, 3D printed patient-specific models have shown tremendous potential to improve clinical outcomes and cost savings,” said
With its unique ability to produce parts in over 360,000 colors, textures, gradients, and transparencies – the Stratasys J750 3D Printer delivers medical models with a broad array of characteristics that replicate the look, feel and function of organic structures. Built directly from patient scans, these models match the widest array of medical properties – from soft tissue to hard bone. Advanced modeling not only guides surgeons in the operating room, but enables patients to better visualize proposed treatments and course of care.
Moving forward, the clinical study is expected to continue into 2018. During the next phase of the project, researchers will begin to explore quantitative patient outcomes.
Corporate Headquarters: Minneapolis,
Online at: www.stratasys.com, http://blog.stratasys.com and LinkedIn.
Attention Editors, if you publish reader-contact information, please use:
USA1-877-489-9449 Europe/ Middle East/ Africa+49-7229-7772-0 Asia Pacific+852 3944-8888
Stratasys Media Contacts
Arita Mattsoff / Joe Hiemenz
Tel. +972 74 745 4000 (IL)
Tel. +1 952 906 2726 (US)
Asia Pacific and Greater China
Tel. +852 3944 8888
Clezia Martins Gomes
Tel. +55 (11) 3129 5158
Tel. +1 518 424 2497
Japan and Korea
Tel. +81 90 6473 1812
Jonathan Wake / Miguel Afonso
Tel. +44 1737 215200
Mexico, Central America, Caribe and South America
Tel. +52 55 4169 4181